Solutions for VCs and Investors
When facing the decision to invest in a biotech start-up it is crucial to de-risk scientific decisions and be sure you are investing in the safest compounds by using the most advanced predictive safety technologies during the due-dilligence.
We help VCs, Business Angels, Corporate and Institutional investors during the due dilligence process, providing the following advantages:
- Quick delivery of results (3-4 weeks)
- Evaluation of main safety risks of compounds or technologies
- Prediction of future potential indications related with the mechanism of action
- Comprehensive future market value evaluation: benchmark against other investigative drugs in class, comparative safety and efficacy, product differentiation, possible combinations and benchmark against standard of care
Today, several top investors trust in Anaxomics services to de-risk and find the better options their investments.
For example, Anaxomics has helped VCs in the scientific due dilligence and in de-risking investments like the following
Safety profile of Drug A and Drug B based on their targets
- A European VC wants to invest in a small pharma that has developed 2 compounds: XYZ_1 and XYZ_2 as HDAC inhibitors.
- They want to select only one compound to move forward, mainly based on the safety profile.
- Anaxomics conducts the comparison of the safety profile between the 2 compounds, and compares them with the class.
- Anaxomics technology predicts safety profile of known compounds with >90% accuracy based on the compound's target profile (different HDAC isoforms).
- Safety profile of new compounds XYZ is predicted with same degree of accuracy.
- VC decides to invest in the compound with the best safety profile, now on safer grounds.